NAD+-converting enzymes in neuronal and glial cells: CD38 as a novel target for neuroprotection

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 10, 2012, Pages 29-37

  Salmina, A B ^a   Inzhutova, A I ^a   Morgun, A V ^a   Okuneva, O S ^a   Malinovskaya, N A ^a   Lopatina, O L ^a   Petrova, M M ^a   Taranushenko, T E ^a   Fursov, A A ^a   Kuvacheva, N V ^a  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

Astrocytes; CD38; Neurons

Indexed keywords

EID: 84871213364     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: 10.15690/vramn.v67i10.413     Document Type: Review

References (69)

1. Doyle K.P, Simon R.P., Stenzel-Poore M.P. Mechanisms of ischemic brain damage. Neuropharmacology. 2008; 55 ( 3): 310-318.
2. Houtkooper R.H., Canto C., Winders RJ., Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocrine Reviews. 2010; 31 ( 2): 194-223.
3. Salmina A.B. Neuron-glia interactions as therapeutic target in neurodegeneration. J. Alzheimer's Disease. 2009; 16 ( 4): 485-502.
4. Virag, L., Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 2002; 54: 375-430.
5. Soane L, Kahraman S., Kristian T., Fiskum G. Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders. J. Neurosci. Res. 2007; 85 (15): 3407-3415. (Pubitemid 350058529)
6. Billington R.A., Travelli C., Ercolano E., Galli U., Roman C.B., Grolla A.A., Canonico P.L., Condorelli F., Genazzani A.A. Characterization of NAD+ uptake in mammalian cells. J. Biol. Chem. 2008; 283 ( 10): 6367-6374.
7. Magni G., Amici A., Emanuelli M., Orsomando G., Raffaelli N., Ruggieri S. Enzymology of NAD+ homeostasis in man. Cell. Mol. Life Sci. 2004; 61: 19-34.
8. Kim M.Y., Zhang T., Kraus WL Poly(ADP-ribosyl)ation by PARPl : «PAR-laying» NAD+ into a nuclear signal. Genes & Development. 2005; 19: 1951-1967.
9. Komjati K., Besson V.C, Szabo C. Poly (ADP-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma. Curr Drug Targets CNS Neurol Disord. 2005; 4 (2): 179-194. (Pubitemid 40601609)
10. Moroni F, Chiarugi A. Post-ischemic brain damage: targeting PARP-1 within the ischemic neurovascular units as a realistic avenue to stroke treatment. Febs J. 2009; 276 ( 1): 36-45.
11. Min W., Wang Z.Q. Poly (ADP-ribose) glycohydrolase (PARP) and its therapeutic potential. Front. Biosci. 2009; 1 ( 14): 1619-1626.
12. Malavasi E, Deaglio S., Funaro A., Ferrero E., Horenstein A.L., Ortolan E., Vaisitti T., Aydin S. Evolution and function of the ADP cibosyl cyclase/CD38 gene family in physiology and pathology. Physiol. Rev. 2008; 88: 841-886.
13. Higashida H., Yokoyama S., Kikuchi M., Munesue T. CD38 and its role in oxytocin secretion and social behavior. Hormones and Behavior. 2012; 61: 351-358.
14. Higashida H., Salmina A.B., Olovyannikova R.Ya., Hashii M., Yokoyama S., Koizumi K., Jin D., Uu H.X., Lopatina O., Amina S., Islam M.S., Huang J.J., Noda M. Cyclic ADP-ribose as a universal calcium signal molecule in the nervous system. Neurochem. Int. 2007; 51:192-199. (Pubitemid 47176716)
15. Cakir-Kiefer C., Muller-SteBher H., Oppenheimer N., Schuber F. Kinetic competence of the cADP-ribose-CD38 complex as an intermediate in the CD38/NAD+ glycohydrolase-catalysed reactions: implication for CD38 signaling. Biochem. J. 2001; 358: 399-406. (Pubitemid 32826356)
16. 2+ elevation by synthetic carbocyclic analogs of cyclic ADP-ribose and their antagonistic effects in NG108-15 neuronal cells. J. Neurochem. 2005; 94 ( 2): 316-323.
17. Higashida H., Hashii M., Yokoyama S., Hoshi N., Chen X.L., Egorova A., Noda M., Zhang J.S. Cyclic ADP-ribose as a second messenger revisited from a new aspect of signal transduction from receptors to ADP-ribosyl cyclase. Pharmacology and Therapeutics. 2001; 90: 283-296.
18. Higashida H., Hashii M., Yokoyama S., Hoshi N., Asai K., Kato T. Cyclic ADP-ribose as a potential second messenger for neuronal Ca2+ signaling. J. Neurochemistiy. 2001; 76:321-331. (Pubitemid 32097011)
19. Ceni C., Pochon N., Villaz M., Muller-Steffner H., Schuber F., Baratier J., De Waard M., Ronjat M., Moutin M.J. The CD38independent ADP-ribosyl cyclase from mouse brain synaptosomes: a comparative study of neonate and adult brain. Biochem. J. 2006; 395: 417-426.
20. Salmina A.B., Okuneva O.S., Malinovskaya NA, Taranushenko T.E., Morgun A.V., Mantorova N.S., Mikhutkina S.V. NAD+-dependent mechanisms of disturbances of viability of brain cells during the acute period of hypoxic-ischemic perinatal injury. J. Neurochem. 2008; 2 ( 3): 215-221.
21. Higashida H., Zhang J.S., Mochida S., Chen X.L., Shin Y., Noda M., Hossain K.Z., Hoshi N., Hashii M., Shigemoto R., Nakanishi S., Fukuda Y., Yokoyama S. Subtype-specific coupling with ADP-ribosyl cyclase of metabotropic glutamate receptors in retina, cervical superior ganglion and NG108-15 cells. J. Neurochem. 2003; 85:1148-1158. (Pubitemid 36613263)
22. Noda M., Yasuda S., Okada M., Higashida H., Shimada A., Iwata N., Ozaki N., Nishikawa K., Shirasawa S., Uchida M., Aoki S., Wada K. Recombinant human 5-HT5A receptors stably expressed in C6 glioma cells couple to multiple signal transduction pathways. J. Neurochem. 2003; 84:222-232. (Pubitemid 36182264)
23. Wilson H.L., Dipp M., Thomas J.T., Lad C., Galione A., Evans A.M. ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase act as redox sensors. J. Biol. Chem. 2001; 276: 1180-1188.
24. 2+ signaling via CD38/ADP-ribosyl cyclase a putative intracellular NAD+ sensor. Faseb J. 2002; 16: 302-314.
25. Ceni C., Muller-Steffher H., Lund F., Pochon N., Schweitzer A., De Waard M., Schuber F., Villaz M., Moutin M.J. Evidence for an intracellular ADP-ribosyl cyclase/NAD+-glycohydrolase in brain from CD38-deficient mice. J Biol. Chem. 2003; 278 (42): 40670-40678. (Pubitemid 37280880)
26. Ma Y, Chen H., He X., Nie H., Hong Y, Sheng C., Wang Q., Xia W., Ying W. NAD+ metabolism and NAD(+)-dependent enzymes: promising therapeutic targets for neurological diseases. Curr Drug Targets. 2012; 13 ( 2): 222-229.
27. Salmina A.B., Olovyannikova R. Ya., M. Noda, and Higashida H. NAD+ metabolism and ADP-ribosyl cyclase as targets for central nervous system therapy. Curr. Median. Chem. 2006; 6:193-210. (Pubitemid 44483709)
28. Aksoy P., White T, Thompson M. Regulation of intracellular levels of NAD+: a novel role for CD38. Biochem. Biophys. Res. Commun. 2006; 10: 1016.
29. Chini E.N. CD38 as a regulator of cellular NAD+: a novel potential pharmacological target for metabolic conditions. Curr. Pharm. Des. 2009; 15 ( 1): 57-63.
30. Outeiro T.F., Marques O., Kazantsev A. Therapeutic role of sirtuins in neurodegenerative disease. Biochim. Biophys. Acta. 2008; 1782: 363-369.
31. Tang B.L., Chua C.E.L. SIRTl and neuronal diseases. Molecular Aspects of Medicine. 2008; 29: 187-200.
32. Cohem D.E., Supinski A.M., Bonkowski M.S., Donmez G., Guarente L.P. Neuronal SIRTl regulates endocrine and behavioral responsestocalorie restriction. Genes & Development. 2009; 23: 2812-2817.
33. Michan S., Li Y., Chou M.M-H., Parrella E., Ge H., Long J.M., Allard J.S., Lewis K., Miller M., Xu W., Mervis R.F., Chen J., Guerin K.I., Smith L.E., McBurney M.W., Sinclair D.A., Baudry M., de Cabo R., Longo V.D. SlRTl is essential for normal cognitive function and synaptic plasticity. J. Neurosci. 2010; 30 ( 29): 9695-9707.
34. Aksoy P., Escande C., White T.A., Thompson M., Soares S., Benech J.C., Chini E.N. Regulation of SlRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. Biochem. Biophys. Res. Commun. 2006; 349:353-359. (Pubitemid 44331799)
35. Sahar S., Nin V., Barbosa M.T., Chini E.N., Sassone-Corsi P. Altered behavioral and metabolic orcadian rhythms in mice with disrupted NAD+ oscillation. Aging. 2011; 3 ( 8): 1-9.
36. Wang S.H., Liao X.M., Liu D., Hu J., Vin Y.Y., Wang J.Z., Zhu L.Q. NGF promotes long-term memory formation by activating poly(ADPribose)polymerase-l. Neuropharmacology. 2012; 63 ( 6): 10851092.
37. 2+ mobilization in dopamine neurons. J. Neurosci. 2003; 23 ( 1): 149-157.
38. Matyash M., Matyash V., Nolte C., Sorrentino V., Kettenmann H. Requirement of functional ryanodine receptor type 3 for astrocyte migration. Faseb J. 2002; 16 ( 1): 84-86.
39. Simpson RB., Holtzclaw L.A., Langley D.B., Russell J.T. Characterization of ryanodine receptors in oligodendrocytes, type 2 astrocytes, and O-2A progenitors. J. Neurosci. Res. 1998; 52 (4): 468-482. (Pubitemid 28259114)
40. Chung K.K., Freestone P.S., Lipski J. Expression and functional properties of TRPM2 channels in dopaminergic neurons of the substantia nigra of the rat. J. Neurophysiol. 2011; 106 ( 6): 2865-2875.
41. Toth B., and Csanady L. Identification of direct and indirect effectors of the transient receptor potential melastatin 2 (TRPM2) cation channel. J.Biol. Chem. 2010; 285 ( 39): 30091-30102.
42. Massullo P., Sumoza-Toledo A., Bhagat H., Partida-Sanchez S. TRPM channels, calcium and redox sensors during innate immune responses. Seminars in Cell & Developmental Biol. 2006; 17:654-666. (Pubitemid 46137024)
43. Naziroglu M. TRPM2 cation channels, oxidative stress and neurological diseases: where are we now? Neurochem Res. 2011; 36 ( 3): 355-366.
44. Lu H., Burns D., Garnier P., Wei G., Zhu K., Ying W. P2X7 receptors mediate NADH transport across the plasma membrane of astrocytes. Biochem. Biophys. Res. Comm. 2007; 362:946-950. (Pubitemid 47390665)
45. Bruzzone S., Basile G., Chothi M.P., Nobbio L, Usai C., Jacchetti E., Schenone A., Guse A.H., Di Virgilio F., De Flora A., Zocchi E. Diadenosine homodinucleotide products of ADP-ribosyl cyclase behave as modulators of the purinergic receptor P2X7. J. Biol. Chem. 2010; 285 ( 27): 21165-21174.
46. +-consuming ectoenzymes in the endocrine system. J. Mol. Endocrinol. 2010; 45: 183-191.
47. Fields R.D., Burnstock G. Purinergic signaling in neuron-glia interactions. Nature Rev. Neurosci. 2006; 7: 423-436
48. + and NADH in astrocytes. Neurochem. Res. 2012. DOI 10.1007/s11064-012-0760-y.
49. Bambrick L., Kristian T., Fiskum G. Astrocyte mitochondrial mechanisms of ischemic brain injury and neuroprotection. Neurochemical Res. 2004; 29 (3): 601-608. (Pubitemid 38295010)
50. Jacobson J., Duchen M.R. Mitochondrial oxidative stress and cell death in astrocytes - requirement for stored Ca2+ and sustained opening of the permeability transition pore. J. Cell Sci. 2002; 115:1175-1188. (Pubitemid 34272482)
51. Sonnewald U., Qu H., Ascher M. Pharmacology and toxicology of astrocyte-neuron glutamate transport and cycling. J. Pharmacol. Exp. Therap. 2002; 301:1-6. (Pubitemid 34250272)
52. Bruzzone S., Dodoni G., Kaludercic N., Basile G., Millo E., De Hora A., Di Lisa F., Zocchi E. Mitochondrial dysfunction induced by a cytotoxic adenine dinucleotide produced by ADP-ribosyl cyclases fromcADPR. J. Biol. Chem. 2007; 282 (7): 5045-5052. (Pubitemid 47100996)
53. Haydon P.G., Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol. Rev. 2006; 86:1009-1031. (Pubitemid 44033387)
54. Nakase T., Sohl G., Theis M., Willecke K., Naus C.C. Increased apoptosis and inflammation after focal brain ischemia in mice lacking connexin 43 in astrocytes. Am. J. Pathol. 2004; 164:2067-2075. (Pubitemid 38669354)
55. De Pina-Benabou M.H., Szostak V., KyrozisA., Rempe D., Uziel D., UrbanMaldonado M., Benabou S., Spray D.C., Federoff H.J., Stanton P.K., Rozentai R. Blockade of gap junctions in vivo provides neuroprotection after perinatal global ischemia. Stroke. 2005; 36:2232-2237. (Pubitemid 41429252)
56. De Flora A., Zocchi E., Guida L., Franco L., Bruzzone S. Autocrine and paracrine calcium signaling by the CD38/NAD+/cyclic ADPribose system. Ann. N.-Y Acad. Sci. 2006; 1028:176-191. (Pubitemid 40372088)
57. Contreras J.E., Sanchez H.A., Eugenin E.A., Speidel D., Theis M., Willecke K., Bukauskas F.F., Bennett M.V., Saez J.C. Metabolic inhibition induces opening of unapposed connexin 43 gap junction hemichannels and reduces gap junctional communication in cortical astrocytes in culture. Proc. Natl. Acad. Sci. 2001; 10: 1073.
58. Bruzzone S., Verderio C., Schenk U., Fedele E., Zocchi E., Matteoli M., De Flora A. Glutamate-mediated overexpression of CD38 in astrocytes cultured with neurons. J. Neurochem. 2004; 89: 264.
59. Winship I.R., Plaa N., Murphy T.H. Rapid astrocyte calcium signals correlate with neuronal activity and onset of the hemodynamic response in vivo. J. Neurosci. 2007; 27:6268-6272. (Pubitemid 46890012)
60. + depletion and mitochondrial permeability transition. J. Biol. Chem. 2004; 279: 18895-18902.
61. Salmina A.B., Malinovskaya N.A., Okuneva O.S., Taranushenko T.E., Fursov A.A., Mihutkina S.V., Morgun A.V., Prokopenko S.V., Zikova L.D. Perinatal hypoxic-ischemic central nervous system damage induces alterations in expression of Cx43, CD38 and activity of ADP-ribosyl cyclase in brain cells. Bull Exp. Biol. Med. 2008; 146 ( 12): 641-645.
62. Salmina A.B., Okuneva O.S., Malinovskaya N.A., Zykova L.D., Fursov AA, Morgun A.Y., Mihutkina S.V., Taranushenko T.E. Changes in expression and activity of CD38 in astroglial cells after impairment of the neuron-glia relationship in the brain induced by perinatal hypoxia-ischemia. J. Neurochem. 2009; 3 ( 3): 207-213.
63. Mayo L., Jacob-Hirsch J., Amariglio N., Rechavi G., Moutin M.J., Lund F.E., Stein R. Dual role of CD38 in microglial activation and activation-induced cell death. J. Immunol. 2008; 181: 92-103.
64. Williams A.C., Cartwright L.S., Ramsden D.B. Parkinson's disease: the first common neurological disease due to auto-intoxication. Q.J. Med. 2005;98:215-226. (Pubitemid 40361319)
65. Levy A, Bercovich-Kinori A., Alexandrovich A.G., Tsenter J., Trembovler V., Lund F.E., Shohami E., Stein R., Mayo L. CD38 facilitates recovery from traumatic brain injury. J. Neurotrauma. 2009; 26: 1521-1533.
66. Miller C.L. The evolution of schizophrenia: a model for selection by infection, with a focus on NAD. Curr. Pharmacol. Des. 2009; 15: 100-109.
67. Salmina A.B., Lopatina O., Ekimova M.V., Milmutkina S.V., Higashida H. CD38/Cyclic ADP-ribose System: A new player for oxytocin secretion and regulation of social behaviour J. Neuroendocrinology. 2010; 22 ( 5): 380-392.
68. Khan J.A., Forouhar F., Tao X., Tong L. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin. Ther. Targets. 2007; 11 (5): 695-705. (Pubitemid 46730083)
69. Ebstein R.P., Mankuta D., Yirmiya N., Malavasi F. Are retinoids potential therapeutic agents in disorders of social cognition including autism? FEBS Lett. 2011; 585 ( 11): 1529-1536.